Mark Otto Baerlocher1, Sean Alexander Kennedy2, Mohammad Reza Rajebi3, Felix J Baerlocher4, Sanjay Misra3, David Liu5, Boris Nikolic6. 1. Division of Vascular and Interventional Radiology, Department of Diagnostic Imaging, Royal Victoria Hospital, Barrie. Electronic address: mark.baerlocher@alumni.utoronto.ca. 2. Department of Diagnostic Imaging, McMaster University, Hamilton, Ontario. 3. Division of Vascular and Interventional Radiology, Department of Radiology, Mayo Clinic, Rochester, Minnesota. 4. Department of Biology, Mount Allison University, Sackville, New Brunswick. 5. Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada. 6. Department of Radiology, Stratton Medical Center, Albany, New York.
Abstract
PURPOSE: To perform a meta-analysis of randomized controlled trials (RCTs) of drug-eluting balloon (DEB) angioplasty and drug-eluting stents (DESs) for infrainguinal peripheral arterial disease. MATERIALS AND METHODS: Systematic searches were performed for all relevant RCTs. RESULTS: Eight RCTs for DEB angioplasty and 12 RCTs for a DES in peripheral arterial disease were identified. Meta-analysis demonstrated statistically significant superiority of DEB over plain balloon angioplasty of femoral-popliteal disease for late lumen loss, restenosis, and target lesion revascularization, with no benefit in major amputation or mortality. Statistically significant superiority of DEB over percutaneous transluminal angioplasty (PTA) was demonstrated for infrapopliteal disease for restenosis and target lesion revascularization. Drug-eluting stents showed statistically significant superiority over bare metal stents (BMSs) of femoral-popliteal disease for late lumen loss and restenosis, with no benefit in mortality or amputation. Drug-eluting stents showed statistically significant superiority over BMSs of infrapopliteal disease restenosis and target lesion revascularization, with no benefit in amputation or mortality. CONCLUSIONS: Drug-eluting balloon angioplasty and DESs demonstrated superior outcomes compared to PTA and BMS, with no difference in amputation or mortality.
PURPOSE: To perform a meta-analysis of randomized controlled trials (RCTs) of drug-eluting balloon (DEB) angioplasty and drug-eluting stents (DESs) for infrainguinal peripheral arterial disease. MATERIALS AND METHODS: Systematic searches were performed for all relevant RCTs. RESULTS: Eight RCTs for DEB angioplasty and 12 RCTs for a DES in peripheral arterial disease were identified. Meta-analysis demonstrated statistically significant superiority of DEB over plain balloon angioplasty of femoral-popliteal disease for late lumen loss, restenosis, and target lesion revascularization, with no benefit in major amputation or mortality. Statistically significant superiority of DEB over percutaneous transluminal angioplasty (PTA) was demonstrated for infrapopliteal disease for restenosis and target lesion revascularization. Drug-eluting stents showed statistically significant superiority over bare metal stents (BMSs) of femoral-popliteal disease for late lumen loss and restenosis, with no benefit in mortality or amputation. Drug-eluting stents showed statistically significant superiority over BMSs of infrapopliteal disease restenosis and target lesion revascularization, with no benefit in amputation or mortality. CONCLUSIONS: Drug-eluting balloon angioplasty and DESs demonstrated superior outcomes compared to PTA and BMS, with no difference in amputation or mortality.
Authors: Hong Kuan Kok; Hamed Asadi; Mark Sheehan; Frank P McGrath; Mark F Given; Michael J Lee Journal: Diagn Interv Radiol Date: 2017 Sep-Oct Impact factor: 2.630
Authors: Marlon I Spreen; Jasper M Martens; Bob Knippenberg; Lukas C van Dijk; Jean-Paul P M de Vries; Jan Albert Vos; Gert Jan de Borst; Evert-Jan P A Vonken; Okker D Bijlstra; Jan J Wever; Randolph G Statius van Eps; Willem P Th M Mali; Hendrik van Overhagen Journal: J Am Heart Assoc Date: 2017-04-14 Impact factor: 5.501